To test the functional roles of ASCL1 and SOX11 in DIPG tumor cells, we used CRISPR/Cas9-mediated gene editing to inactivate them individually and in combination in ACVR1 mutant (SU-DIPG-IV, SU-DIPG-XXI, SU-DIPG-XXXVI, HSJD-DIPG-007) or wild-type (SU-DIPG-VI) cells. This evidence concerns the gene ACVR1 and neoplasm.